Skip to content

Bellipharma: sector benchmark

Where does a company stand against its sector? Every ratio over five fiscal years, with its place among its peers and what that means, ready to print for your client.

Sector benchmark

Bellipharma

BE 0844.039.461
NACE 47.730, Retail sale of pharmaceutical products
NACE division 47, Retail trade all sizesfiscal years 2021 to 20253,139 to 32,568 sector peers per ratio

Summary

fiscal year 2025

Bellipharma does better than half of its sector on 3 of the 14 ratios compared.

most favourable quarter above the median below the median least favourable quarter
Strongest points
  • EBITDA marginbetter than 80%
  • Net marginbetter than 72%
  • Long-term debt ratiobetter than 51%
Points to watch
  • Return on equitybetter than 17%
  • Days sales outstandingbetter than 21%
  • Working-capital ratiobetter than 21%

Solvency and debt

How soundly the company is financed.
Solvency
29.8%▼2025

Solvency is below 57% of 32,488 sector peers: less favourable than the median.

Position against the sector weakening since 2021.

20212022202320242025
Debt to equity
2.35▲2025

Debt to equity is above 73% of 32,106 sector peers: less favourable than the median.

Position against the sector weakening since 2021.

20212022202320242025
Long-term debt ratio
0.31▼2025

The long-term debt ratio is below 51% of 16,997 sector peers: more favourable than the median.

Position against the sector improving since 2021.

20212022202320242025
Interest coverage
6.79▼2025

Interest coverage is below 54% of 29,199 sector peers: less favourable than the median.

Position against the sector weakening since 2021.

20212022202320242025

Liquidity

Whether it can pay its short-term bills.
Current ratio
0.85▼2025

The current ratio is below 78% of 32,316 sector peers: in the least favourable quarter.

Position against the sector weakening since 2021.

20212022202320242025
Quick ratio
0.38▼2025

The quick ratio is below 75% of 32,337 sector peers: in the least favourable quarter.

Position against the sector weakening since 2021.

20212022202320242025
Working-capital ratio
-8.9%▼2025

The working-capital ratio is below 79% of 32,412 sector peers: in the least favourable quarter.

Position against the sector weakening since 2021.

20212022202320242025

Profitability

What the company earns on its assets and its sales.
Return on equity
-4.4%▼2025

Return on equity is below 83% of 27,017 sector peers: in the least favourable quarter.

Position against the sector weakening since 2021.

20212022202320242025
Return on assets
-1.3%▼2025

Return on assets is below 74% of 32,568 sector peers: less favourable than the median.

Position against the sector weakening since 2021.

20212022202320242025
Net margin
3.9%2022

The net margin is above 72% of 3,804 sector peers: more favourable than the median.

20212022202320242025
EBITDA margin
11.4%2022

The EBITDA margin is above 80% of 3,139 sector peers: in the most favourable quarter.

20212022202320242025
Gross margin
11.9%2022

The gross margin is around the median of 3,750 sector peers.

20212022202320242025

Working-capital cycle

How long cash is tied up in customers, suppliers and stock.
Days sales outstanding
50days2022

Days sales outstanding is above 79% of 3,554 sector peers: in the least favourable quarter.

20212022202320242025
Days payable outstanding
43days2022

Days payable outstanding is above 59% of 3,886 sector peers.

20212022202320242025
Days inventory
66days2022

Days inventory is above 56% of 3,463 sector peers: less favourable than the median.

20212022202320242025

Source: filed annual accounts (NBB) and main activity (CBE register). Compared per fiscal year with each peer's latest statutory accounts; at least 30 peers per ratio. Prepared on 29 September 2026 via checked.be.